Developer docs
API playgroundTry for free, no card

Search company profiles

BOYDSense

Full company profile

uuid0002o3d

Namestring
BOYDSense
Legal namestring
BOYDSense SAS
Websiteurl
boydsense.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

BOYDSense is a Toulouse, France-based MedTech company and majority-owned subsidiary of Alpha MOS (Euronext Paris: ALNEO), developing non-invasive breath analysis devices for chronic disease monitoring. Its flagship product, the "Lassie" device, uses proprietary Metal Oxide (MOx) sensor arrays to detect and quantify Volatile Organic Compounds (VOCs) in exhaled breath, with embedded on-board algorithms translating sensor signals into blood glucose estimates. The first application targets non-invasive glucose monitoring for people with Type 2 diabetes, with a stated future pipeline extending to sepsis detection and fatty liver disease monitoring. The company has completed four clinical trials with over 370 subjects, including the BOYDSense-GM Study with 130 type 2 diabetes adults that achieved 98.7% of estimates in clinically acceptable Parkes error grid zones A/B and was published in the Journal of Diabetes Science and Technology.

The business model is a regulated medical device commercialization play: primary revenue is expected from hardware sales of the Lassie device (with associated consumables), supplemented by cloud-connected subscription or service revenue from data sharing and connected healthcare features. Pricing is not publicly disclosed. The go-to-market motion is enterprise field sales targeting healthcare providers (diabetologists, endocrinologists, hospitals) and insurance reimbursement channels, with a US subsidiary (BOYDSense, Inc.) in South San Francisco supporting North American ambitions. The company has raised approximately €9.5 million to date (€2.5M European Innovation Council grant in 2022 plus a €7M capital increase in April 2024), achieved ISO 13485 certification in March 2026, and is targeting regulatory market authorization around 2027. Current operating scale is small (1-10 employees), and the company remains pre-revenue pending regulatory clearance.

Short descriptiontext

BOYDSense develops non-invasive breath analysis devices for chronic disease monitoring. Its flagship "Lassie" device uses proprietary MOx sensor arrays and embedded algorithms to estimate blood glucose from exhaled VOCs, targeting Type 2 diabetes patients, pre-diabetics, and healthcare providers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersToulouse, France
HQ citystring
Toulouse
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
breath analysis devices, non-invasive glucose monitoring, diabetes medical devices, VOC sensor technology, metabolic biomarker detection
Industry3 codes
PRIMARYHLAHACAD
Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLAHAGAI
Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAHAGAH
Pulmonary Function Testing (PFT) & Spirometry Equipment
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code3 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
  • Laboratory Analytical Instruments3826
Product category
Non-invasive glucose monitoring devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Sales
TypeHardware Sales
Description

BOYDSense develops and plans to commercialize a non-invasive breath analysis device (Lassie) for glucose monitoring. Revenue will be generated through device sales, likely accompanied by consumables and ongoing software/cloud services for data analysis and connectivity.

boydsense.com
2Connected Healthcare Solutions
TypeSubscription Recurring
Description

On-board analysis algorithms delivering direct results connected with the Cloud for sharing data as part of a connected healthcare solution, potentially generating recurring software/service revenue.

boydsense.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

BOYDSense develops a non-invasive breath analysis medical device (named Lassie) that measures blood glucose levels by detecting and analyzing volatile organic compounds (VOCs) in exhaled breath using proprietary Metal Oxide (MOx) sensor arrays and embedded on-board algorithms. The device delivers direct results as a stand-alone unit or connected to the cloud, providing a pain-free alternative to finger-prick blood glucose monitoring for people with Type 2 diabetes.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 98.7% of glucose estimates in clinically acceptable Parkes error grid zones A/B (T1D grid); 99.7% in T2D grid
+4 more records
Product overview1 text field

BOYDSense offers a breath-based health monitoring platform anchored by its Lassie device and supporting technologies. Lassie is a non-invasive glucose monitoring device that analyzes exhaled breath VOCs as a pain-free alternative to finger-prick testing. The platform includes proprietary MOx sensor arrays and breath sampling modules, with on-board analysis algorithms that deliver direct results as a stand-alone device or connected via Cloud for data sharing. The first application targets diabetes management, with future pipeline for sepsis and fatty liver disease detection and monitoring.

Product and service2 records
1Lassie Breath Glucose Monitoring Device
CategoryNon-invasive glucose monitoring device
Description

Non-invasive breath analysis device that measures blood glucose levels through analysis of exhaled volatile organic compounds (VOCs), providing a pain-free alternative to finger-prick blood glucose monitoring. Uses proprietary MOx sensor arrays and on-board algorithms to deliver direct glucose estimates as a stand-alone device or connected to the cloud, targeted at people with Type 2 diabetes and prescribed by healthcare providers.

2Breath-based VOC Analyzer Platform
CategoryBreath analysis medical device platform
Description

Miniaturized breath analysis platform that analyzes exhaled metabolites (VOCs) for monitoring chronic diseases, combining proprietary MOx sensors, breath sampling modules, and on-board analysis algorithms. First commercial application is diabetes monitoring; future pipeline targets sepsis and fatty liver disease detection and monitoring.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Seleon GmbH
Strategic tierSupportingTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-03-17
Description

Partner company that provided expertise and support for achieving ISO 13485 certification for BOYDSense's quality management system.

boydsense.com
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2024-03-17
Description

Strategic Project Council (SPC) of Eurobiomed supported BOYDSense within an EIC Accelerator application, recognizing its medical innovation.

3Toulouse University Hospital (CHU)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-06-01
Description

Promoted the 2nd BOYDSense clinical study launched in late 2021. The Diabetology, Metabolic Diseases and Nutrition research team conducted studies involving 130 patients with Type 2 diabetes. Principal investigator Prof. Pierre Gourdy led the research.

boydsense.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-06-01
Description

Parent company (EuroNext: ALNEO) that founded BOYDSense as a MedTech subsidiary. Alpha MOS is a world leader in smell, taste and visual industrial instrument analyzers. BOYDSense leverages Alpha MOS technology and expertise in sensor development.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Public company developing non-invasive glucose monitoring using radiofrequency spectroscopy. Most direct competitor pursuing a non-invasive alternative to fingerstick/CGM, targeting similar patient populations with comparable pre-revenue/regulatory profile.

TypeOthers
Description

Owner of Accu-Chek and mySugr (acquired 2017); BOYDSense Board Chair Anton Kittelberger is the mySugr founder. Strategic acquirer/partner candidate in the glucose monitoring ecosystem with deep digital diabetes expertise.

TypeEmerging player
Description

Berlin-based developer of non-invasive glucose monitoring using infrared spectroscopy through the skin. Emerging peer in the non-invasive glucose monitoring category with a different technical approach but identical target use case.

TypeBroad incumbent
Description

Maker of OneTouch blood glucose monitoring systems, formerly J&J Diabetes Care. Broad incumbent in glucose self-monitoring; BOYDSense CEO Ben Delhey previously led OneTouch launches globally, providing a direct execution playbook comparison.

TypeDirect peer
Description

Developer of Eversense, the first long-term implantable CGM (up to 180 days). Direct peer as a glucose monitoring innovator pursuing an alternative measurement modality to standard CGM with a similar long-path-to-market profile.

TypeEmerging player
Description

Early-stage company developing a breath-based diabetes monitor using similar VOC detection principles. Direct emerging peer in the breath-glucose niche, pursuing the same patient use case from a smaller, US-based footprint.

TypeBroad incumbent
Description

Manufacturer of Guardian Connect CGM and MiniMed insulin pumps. Broad incumbent in diabetes device ecosystem; comparable as a major diabetes monitoring technology provider competing for the same patient population.

TypeBroad incumbent
Description

Maker of FreeStyle Libre, the dominant flash glucose monitoring system globally. Largest installed base in glucose monitoring; BOYDSense's non-invasive approach is positioned against Abbott's expanding CGM roadmap.

TypeDirect peer
Description

Developer of sugarBEAT, a non-invasive continuous glucose monitor worn as a patch. Direct peer in the non-invasive glucose monitoring category, also pre-commercial and targeting similar regulatory milestones.

TypeBroad incumbent
Description

Global leader in continuous glucose monitoring (CGM) with the G6/G7 product family. Most directly comparable competitor in glucose monitoring; BOYDSense must beat incumbents on non-invasiveness since CGM accuracy and reimbursement are already deeply established.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BOYDSense

Non-invasive glucose monitoring devicesboydsense.com

BOYDSense develops non-invasive breath analysis devices for chronic disease monitoring. Its flagship "Lassie" device uses proprietary MOx sensor arrays and embedded algorithms to estimate blood glucose from exhaled VOCs, targeting Type 2 diabetes patients, pre-diabetics, and healthcare providers.

What BOYDSense does

BOYDSense is a Toulouse, France-based MedTech company and majority-owned subsidiary of Alpha MOS (Euronext Paris: ALNEO), developing non-invasive breath analysis devices for chronic disease monitoring. Its flagship product, the "Lassie" device, uses proprietary Metal Oxide (MOx) sensor arrays to detect and quantify Volatile Organic Compounds (VOCs) in exhaled breath, with embedded on-board algorithms translating sensor signals into blood glucose estimates. The first application targets non-invasive glucose monitoring for people with Type 2 diabetes, with a stated future pipeline extending to sepsis detection and fatty liver disease monitoring. The company has completed four clinical trials with over 370 subjects, including the BOYDSense-GM Study with 130 type 2 diabetes adults that achieved 98.7% of estimates in clinically acceptable Parkes error grid zones A/B and was published in the Journal of Diabetes Science and Technology.

The business model is a regulated medical device commercialization play: primary revenue is expected from hardware sales of the Lassie device (with associated consumables), supplemented by cloud-connected subscription or service revenue from data sharing and connected healthcare features. Pricing is not publicly disclosed. The go-to-market motion is enterprise field sales targeting healthcare providers (diabetologists, endocrinologists, hospitals) and insurance reimbursement channels, with a US subsidiary (BOYDSense, Inc.) in South San Francisco supporting North American ambitions. The company has raised approximately €9.5 million to date (€2.5M European Innovation Council grant in 2022 plus a €7M capital increase in April 2024), achieved ISO 13485 certification in March 2026, and is targeting regulatory market authorization around 2027. Current operating scale is small (1-10 employees), and the company remains pre-revenue pending regulatory clearance.

BOYDSense firmographics

Firmographics
Name
BOYDSense
Legal name
BOYDSense SAS
Website
https://boydsense.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
BOYDSense develops non-invasive breath analysis devices for chronic disease monitoring. Its flagship "Lassie" device uses proprietary MOx sensor arrays and embedded algorithms to estimate blood glucose from exhaled VOCs, targeting Type 2 diabetes patients, pre-diabetics, and healthcare providers.
Ownership category
akta.pro rank

BOYDSense industry classification

Industry
Product category
Non-invasive glucose monitoring devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAHACAD
Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLAHAGAI
Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices
SECONDARYHLAHAGAH
Pulmonary Function Testing (PFT) & Spirometry Equipment
Healthcare & Life Sciences/Medical Devices & Diagnostics/Respiratory & Sleep Therapy Devices

Keywords

  • Breath analysis devices
  • Non-invasive glucose monitoring
  • Diabetes medical devices
  • VOC sensor technology
  • Metabolic biomarker detection

Where BOYDSense is headquartered

Location

Headquarters

HQ city
Toulouse
HQ country
France
HQ region
Europe

Offices2 records

Markets served

BOYDSense business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Medical Device Sales: BOYDSense develops and plans to commercialize a non-invasive breath analysis device (Lassie) for glucose monitoring. Revenue will be generated through device sales, likely accompanied by consumables and ongoing software/cloud services for data analysis and connectivity.
  2. Connected Healthcare Solutions: On-board analysis algorithms delivering direct results connected with the Cloud for sharing data as part of a connected healthcare solution, potentially generating recurring software/service revenue.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

BOYDSense product offering

Product offering

Core offering

BOYDSense develops a non-invasive breath analysis medical device (named Lassie) that measures blood glucose levels by detecting and analyzing volatile organic compounds (VOCs) in exhaled breath using proprietary Metal Oxide (MOx) sensor arrays and embedded on-board algorithms. The device delivers direct results as a stand-alone unit or connected to the cloud, providing a pain-free alternative to finger-prick blood glucose monitoring for people with Type 2 diabetes.

Product overview

BOYDSense offers a breath-based health monitoring platform anchored by its Lassie device and supporting technologies. Lassie is a non-invasive glucose monitoring device that analyzes exhaled breath VOCs as a pain-free alternative to finger-prick testing. The platform includes proprietary MOx sensor arrays and breath sampling modules, with on-board analysis algorithms that deliver direct results as a stand-alone device or connected via Cloud for data sharing. The first application targets diabetes management, with future pipeline for sepsis and fatty liver disease detection and monitoring.

Differentiator

Problem solved

Functional benefit

Products and services

  • Lassie Breath Glucose Monitoring Device Non-invasive breath analysis device that measures blood glucose levels through analysis of exhaled volatile organic compounds (VOCs), providing a pain-free alternative to finger-prick blood glucose monitoring. Uses proprietary MOx sensor arrays and on-board algorithms to deliver direct glucose estimates as a stand-alone device or connected to the cloud, targeted at people with Type 2 diabetes and prescribed by healthcare providers.
  • Breath-based VOC Analyzer Platform Miniaturized breath analysis platform that analyzes exhaled metabolites (VOCs) for monitoring chronic diseases, combining proprietary MOx sensors, breath sampling modules, and on-board analysis algorithms. First commercial application is diabetes monitoring; future pipeline targets sepsis and fatty liver disease detection and monitoring.

Quantifiable outcome

  • 98.7% of glucose estimates in clinically acceptable Parkes error grid zones A/B (T1D grid); 99.7% in T2D grid
  • +4 more outcomes

Companies that use BOYDSense

Customer profile

Segments4 records

Ideal customer profiles4 records

BOYDSense technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

BOYDSense partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered supporting and core.

  • Seleon GmbHsupportingImplementation/ SI/ Consulting Partner · 17 March 2026Partner company that provided expertise and support for achieving ISO 13485 certification for BOYDSense's quality management system.
  • EurobiomedsupportingStrategic or Co-development Partner · 17 March 2024Strategic Project Council (SPC) of Eurobiomed supported BOYDSense within an EIC Accelerator application, recognizing its medical innovation.
  • Toulouse University Hospital (CHU)coreStrategic or Co-development Partner · 1 June 2021Promoted the 2nd BOYDSense clinical study launched in late 2021. The Diabetology, Metabolic Diseases and Nutrition research team conducted studies involving 130 patients with Type 2 diabetes. Principal investigator Prof. Pierre Gourdy led the research.
  • Alpha MOScoreStrategic or Co-development Partner · 1 June 2020Parent company (EuroNext: ALNEO) that founded BOYDSense as a MedTech subsidiary. Alpha MOS is a world leader in smell, taste and visual industrial instrument analyzers. BOYDSense leverages Alpha MOS technology and expertise in sensor development.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

BOYDSense competitors and assessment

Company assessment

Direct peers

  • Know Labs: Public company developing non-invasive glucose monitoring using radiofrequency spectroscopy. Most direct competitor pursuing a non-invasive alternative to fingerstick/CGM, targeting similar patient populations with comparable pre-revenue/regulatory profile.
  • Senseonics: Developer of Eversense, the first long-term implantable CGM (up to 180 days). Direct peer as a glucose monitoring innovator pursuing an alternative measurement modality to standard CGM with a similar long-path-to-market profile.
  • Nemaura Medical: Developer of sugarBEAT, a non-invasive continuous glucose monitor worn as a patch. Direct peer in the non-invasive glucose monitoring category, also pre-commercial and targeting similar regulatory milestones.

Others

  • Roche Diabetes Care: Owner of Accu-Chek and mySugr (acquired 2017); BOYDSense Board Chair Anton Kittelberger is the mySugr founder. Strategic acquirer/partner candidate in the glucose monitoring ecosystem with deep digital diabetes expertise.

Emerging players

  • DiaMonTech: Berlin-based developer of non-invasive glucose monitoring using infrared spectroscopy through the skin. Emerging peer in the non-invasive glucose monitoring category with a different technical approach but identical target use case.
  • AerBetic: Early-stage company developing a breath-based diabetes monitor using similar VOC detection principles. Direct emerging peer in the breath-glucose niche, pursuing the same patient use case from a smaller, US-based footprint.

Broad incumbents

  • LifeScan: Maker of OneTouch blood glucose monitoring systems, formerly J&J Diabetes Care. Broad incumbent in glucose self-monitoring; BOYDSense CEO Ben Delhey previously led OneTouch launches globally, providing a direct execution playbook comparison.
  • Medtronic Diabetes: Manufacturer of Guardian Connect CGM and MiniMed insulin pumps. Broad incumbent in diabetes device ecosystem; comparable as a major diabetes monitoring technology provider competing for the same patient population.
  • Abbott Diabetes Care: Maker of FreeStyle Libre, the dominant flash glucose monitoring system globally. Largest installed base in glucose monitoring; BOYDSense's non-invasive approach is positioned against Abbott's expanding CGM roadmap.
  • Dexcom: Global leader in continuous glucose monitoring (CGM) with the G6/G7 product family. Most directly comparable competitor in glucose monitoring; BOYDSense must beat incumbents on non-invasiveness since CGM accuracy and reimbursement are already deeply established.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

BOYDSense social profiles

Digital presence

BOYDSense compliance and trust

Trust signal

Compliance1 record

BOYDSense financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BOYDSense leadership team

Management profile

Number of profiles

Profiles7 records

BOYDSense funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BOYDSense M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BOYDSense

What does BOYDSense do?

BOYDSense develops a non-invasive breath analysis medical device (named Lassie) that measures blood glucose levels by detecting and analyzing volatile organic compounds (VOCs) in exhaled breath using proprietary Metal Oxide (MOx) sensor arrays and embedded on-board algorithms. The device delivers direct results as a stand-alone unit or connected to the cloud, providing a pain-free alternative to finger-prick blood glucose monitoring for people with Type 2 diabetes.

Is BOYDSense a public or private company?

BOYDSense is a private company. It is classified as venture growth investor backed and is currently operating.

When was BOYDSense founded?

BOYDSense was founded in 2020. It employs 11 to 50 people.

Where is BOYDSense based?

BOYDSense is headquartered in Toulouse, France, in the Europe region.

How does BOYDSense make money?

Two revenue lines are on record. Medical Device Sales are the primary driver. The others are connected Healthcare Solutions.

Who are BOYDSense's main competitors?

Direct peers on record are Know Labs, Senseonics and Nemaura Medical. Roche Diabetes Care is listed as an others. Emerging players are DiaMonTech and AerBetic. Broad incumbents are LifeScan, Medtronic Diabetes, Abbott Diabetes Care and Dexcom.

Does BOYDSense have an API?

No public API is recorded for BOYDSense.

What industry is BOYDSense in?

BOYDSense's product category is Non-invasive glucose monitoring devices. Its primary akta.pro industry code is HLAHACAD, Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry), with a secondary code of HLAHAGAI, Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Biotech FinancesDIABÈTE : BOYDSENSE LÈVE 7 M€ ET ÉTEND SA VISIBILITÉ À MI-2025BOYDSense, a medical technology company and subsidiary of Alpha Mos, has raised €7 million in capital to fund clinical trials and the development of its non-invasive breath-based glucose monitoring device, Lassie. The funding extends the company's financial visibility through mid-2025 as it prepares for European regulatory approval (AMM) expected around 2027. This investment supports further studies with the Toulouse University Hospital and other European partners to validate the device for the global diabetic population.Jolt CapitalBOYDSense raises an additional €7M — Jolt CapitalBOYDSense has completed a €7 million capital increase to accelerate the development of its non-invasive breath-based glucose monitoring device. The financing round was led by the Swiss Diabetes Venture Fund and Bioserenity, with participation from the European Innovation Council Fund, Jolt Capital, and Ambrosia Investments. These funds will support new clinical studies, certification processes for marketing authorization, and further product miniaturization.BoydsenseBOYDSense raises €7m in a capital increase to further develop its non-invasive glucose monitoring device.BOYDSense has successfully raised €7 million through a capital increase to advance the development of its non-invasive glucose monitoring device. This funding, which includes contributions from new investors such as Swiss Diabetes Venture Fund and Bioserenity, will support further clinical studies and enhance the company's capabilities to obtain necessary certifications for market launch. The company aims to revolutionize health monitoring through their innovative technology.PR NewswireNon-invasive Glucose Monitoring Devices Market Size to Grow by USD 11.35 million, BOYDSense Inc. and Cnoga Medical Ltd. Among Key Vendors - TechnavioTechnavio forecasts the non-invasive glucose monitoring devices market to grow by USD 11.35 million from 2020 to 2025, accelerating at a CAGR of 11.05%. North America is projected to account for 56% of the growth, with the wearable segment expected to see significant market share expansion.Alpha-MosThe Strategic Project Council (SPC) of Eurobiomed declares its support to BOYDSense, the MedTech subsidiary of Alpha MOSEurobiomed's Strategic Project Council has declared support for BOYDSense, the MedTech subsidiary of Alpha MOS, in its application for an EIC Accelerator grant. This endorsement follows BOYDSense's selection for a €2.5M grant from the European Innovation Council to develop a miniaturized breath analyzer for monitoring blood glucose levels. The recognition highlights the company's medical innovation and validates its progress within the French healthtech ecosystem.PR NewswireBOYDSense diabetes device places among top innovations at 2019 RESI Innovation ChallengeMedical technology company BOYDSense, Inc. secured second place in the RESI Innovation Challenge at a biotech conference in Boston for its g-Sense Breath Meter. The device is designed to predict blood glucose values non-invasively by measuring volatile organic compounds in human breath. This recognition from investors and peers aims to boost the company's momentum toward commercializing its first product.PR NewswireEl dispositivo para la diabetes de BOYDSense se ubica entre las principales innovaciones en el Desafío a la Innovación RESI 2019BOYDSense, Inc. won second place at the RESI Innovation Challenge 2019 in Boston, a major investment conference for biotech and medical technology organized by Life Science Nation, with its g-Sense Breath Meter selected as a winner among 130 initial participants and 38 finalists.PR NewswireEl dispositivo para la diabetes de BOYDSense destaca como innovación en el Desafío de Innovación de la RESI 2019BOYDSense, Inc. placed second in the RESI 2019 Innovation Challenge held in Boston at the Redefining Early Stage Investments conference organized by Life Science Nation. The company's g-Sense Breath Meter, a non-invasive handheld device that predicts blood glucose values by measuring volatile organic compounds in human breath, was selected as a finalist from 130 entries and then chosen as a winner through attendee voting among 38 finalists. BOYDSense CEO Bruno Thuillier stated that the recognition reinforces the company's roadmap toward commercializing its first product for people with diabetes.PR NewswireBOYDSense überzeugt auf RESI Innovation Challenge mit Diabetes-Gerät als eine der Top-InnovationenMedtech company BOYDSense won second place at the RESI Innovation Challenge 2019 in Boston, a major early-stage investment conference for biotech and medtech, securing additional investor accolades among 130 applicants and 38 finalists. The company's g-Sense Breath Meter, a handheld non-invasive device that measures volatile organic compounds in breath to predict blood glucose values, was presented by CEO Bruno Thuillier and VP Joel Rabasco to approximately 350 investors and startups at the event. BOYDSense, a subsidiary of VOC analysis market leader Alpha MOS, stated the recognition reinforces its commitment to bringing its first commercial product to the diabetes market.PR NewswireLe dispositif de BOYDSense pour les diabétiques se classe parmi les meilleures innovations au RESI Innovation Challenge 2019BOYDSense, Inc., a medical technology company, won second place at the RESI Innovation Challenge 2019 in Boston with its g-Sense Breath Meter, a non-invasive handheld device that predicts blood glucose levels by measuring volatile organic compounds (VOCs) in human breath. The company was selected as a finalist among 38 contenders out of 130 initial participants at one of the year's largest investment conferences for biotechnology and medical technology. The company stated the accolade will strengthen its momentum toward commercializing the device and making it available to diabetic patients.